18-MC, a novel iboga
alkaloid congener, is being developed as a potential treatment for multiple forms of
drug abuse. Like
ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous
self-administration of
morphine and
cocaine and the oral
self-administration of
ethanol and
nicotine in rats; unlike
ibogaine, 18-MC does not affect responding for a nondrug reinforcer (water). Both
ibogaine and 18-MC ameliorate
opioid withdrawal signs. Both
ibogaine and 18-MC decrease extracellular levels of
dopamine in the nucleus accumbens, but only
ibogaine increases extracellular levels of
serotonin in the nucleus accumbens. Both
ibogaine and 18-MC block
morphine-induced and
nicotine-induced
dopamine release in the nucleus accumbens; only
ibogaine enhances
cocaine-induced increases in accumbal
dopamine. Both
ibogaine and 18-MC enhance the locomotor and/or stereotypic effects of stimulants.
Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of
morphine; both compounds attenuate
morphine-induced locomotion in
morphine-experienced rats.
Ibogaine produces whole body
tremors and, at high doses (> or = 100 mg/kg), cerebellar damage; 18-MC does not produce these effects.
Ibogaine, but not 18-MC, decreases heart rate at high doses. While 18-MC and
ibogaine have similar affinities for kappa
opioid and possibly
nicotinic receptors, 18-MC has much lower affinities than
ibogaine for
NMDA and
sigma-2 receptors,
sodium channels, and the
5-HT transporter. Both 18-MC and
ibogaine are sequestered in fat and, like
ibogaine, 18-MC probably has an active metabolite. The data suggest that 18-MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than
ibogaine.